Related Experiment Video
Updated: Apr 21, 2026
07:13
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
Published on: December 7, 2016
14.1K
Orbital hemorrhage after intravitreal injection.
Gary Shienbaum1, Richard S Kaiser, Scott M Goldstein
1*Retina Service †Oculoplastics and Orbital Surgery Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania.
Retinal Cases & Brief Reports
|November 13, 2014
Summary
Intravitreal ranibizumab injections can cause orbital hemorrhage, especially in patients on anticoagulation therapy. This case highlights a rare complication following treatment for age-related macular degeneration.
Area of Science:
- Ophthalmology
- Vascular Medicine
Background:
- Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss.
- Intravitreal injections are a common treatment for AMD.
- Complications, though rare, can occur.
Purpose of the Study:
- To report a case of orbital hemorrhage following intravitreal ranibizumab administration.
- To highlight a potential risk in anticoagulated patients.
Main Methods:
- Retrospective chart review of a single patient case.
- Clinical examination and patient history analysis.
Main Results:
- A 73-year-old female on coumadin anticoagulation (INR 3.4) developed orbital hemorrhage post-intravitreal ranibizumab.
- The hemorrhage extended from a bullous subconjunctival hemorrhage.
- Symptoms included decreased vision and metamorphopsia.
Conclusions:
- Intravitreal injections carry a risk of orbital hemorrhage.
- Anticoagulated patients may be at increased risk.
- Careful patient selection and monitoring are crucial.
